Hemab Therapeutics Holdings reported total assets of $442.71M and total liabilities of $13.44M for the quarter ended Sep 2026. This balance sheet covers 8 quarters of results from Dec 2024 through Sep 2026, standardized by Business Quant from the company’s SEC filings.
| Balance SheetBalance Sheet | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 | Sep2026 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current Assets | ||||||||
| Cash & EquivalentsCash & Equiv. | 74.41M | 87.97M | 49.86M | 237.37M | 239.15M | |||
| Short-term InvestmentsInvestments (Current) | 13.92M | 97.51M | 113.67M | 220.09M | 191.09M | |||
| Cash & Current Investments | 88.33M | 185.49M | 163.53M | 457.46M | 430.24M | |||
| Receivables - OtherOther Receivables | 2.63M | 1.43M | 1.82M | 1.21M | ||||
| Prepaid Assets | 4.91M | 7.07M | 5.90M | 6.54M | 7.92M | |||
| Current Assets | 93.24M | 192.55M | 169.43M | 464.00M | 438.16M | |||
| Non-Current Assets | ||||||||
| Property, Plant & Equipment (Net)PP&E (Net) | 0.90M | 0.61M | 0.65M | 0.60M | 0.56M | |||
| Other Non-Current Assets | 0.48M | 0.53M | 4.24M | 2.29M | 3.15M | |||
| Non-Current Assets | 3.04M | 2.23M | 5.83M | 3.78M | 4.55M | |||
| Assets | 96.28M | 194.78M | 175.26M | 467.78M | 442.71M | |||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payables | 3.16M | 5.73M | 5.68M | 6.23M | 5.95M | |||
| Payables | 3.16M | 5.73M | 5.68M | 6.23M | 5.95M | |||
| Accumulated Expenses | 2.86M | 4.30M | 6.96M | 6.25M | 6.53M | |||
| Other Accumulated Expenses | 0.34M | 0.99M | 1.20M | |||||
| Total Current Liabilities | 6.69M | 10.68M | 13.19M | 12.94M | 12.94M | |||
| Non-Current Liabilities | ||||||||
| Preferred Stock Liabilities | 360.17M | |||||||
| Operating Leases | 1.06M | 0.57M | 0.52M | 0.57M | 0.50M | |||
| Other Non-Current Liabilities | 0.06M | |||||||
| Total Non-Current Liabilities | 211.49M | |||||||
| Total Liabilities | 211.55M | 371.42M | 373.88M | 13.51M | 13.44M | |||
| Shareholder's Equity | ||||||||
| Common Equity | -115.27M | -129.15M | -141.47M | -158.00M | -176.64M | -198.62M | 454.27M | 429.27M |
| Liabilities and Shareholders Equity | 96.28M | 194.78M | 175.26M | 467.78M | 442.71M | |||
| Retained Earnings | -117.95M | -181.86M | -204.55M | -228.70M | -256.00M | |||
| Preferred Shares | 360.17M | 360.17M |
Pull Hemab Therapeutics Holdings's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=COAG&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "COAG", "statement": "BS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=COAG&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();